A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

Dec. 18, 2024 — Dancing lowers the depression associated with Parkinson's disease, and the benefits can be seen in multiple ways, a new study ... Nov. 19, 2024 — A recently published study ...

An obesity medicine physician writes that weight-loss drugs such as Ozempic have been getting a bad rap, almost as if those ...

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

They're known to aid in blood sugar control and, now, weight loss — however, according to a sweeping new study, the popular ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...